For people suffering from Primary bone cancer — which is cancer that starts in the bones — a promising new drug may be on the horizon.
The drug, called CADD522, works by blocking a gene called RUNX2, which is important for the process of bone formation in cancer patients.
In a recent study in mice, CADD522 significantly reduced tumor volume, increased survival and reduced cancer-induced bone disease—all without surgery.
Most men with prostate cancer don’t need to rush to surgery, radiation treatments: Study
The study, which appeared in the Journal of Bone Oncology, was led by the University of East Anglia. Norwich, EnglandWith researchers from the University of Sheffield, the University of Newcastle, the Royal Orthopedic Hospital in Birmingham, and Norfolk and Norwich University Hospitals.
Molecular biologist of the University of East Anglia, principal researcher Dr. Darrell Green told Fox News Digital that there has been no new treatment for bone cancer for 45 years. “This new drug, if approved, would be the first new drug in decades,” he said in an email.
Osteosarcoma, the most common type of bone cancer, mainly affects children and young adults. About a promising new drug, the lead researcher told Fox News Digital, “The drug attacks only the cancer cells and leaves the rest of the body alone.” (iStock)
In preclinical trials, CADD522 resulted in a 50% increase in survival for all major types of bone cancer — without chemotherapy or surgery, Green said.
He hopes survival will improve further with more treatments.
“Also, because it’s a targeted drug, we haven’t seen side effects yet,” Green added. “The medicine only attacks the cancer cells and leaves the rest of the body alone.”
The FDA issued new mammogram regulations to further prevent breast cancer
Greene was inspired to study childhood bone cancer after her best friend died of the disease as a teenager.
“I hope that my work and the development of this new drug makes him proud and carries on his legacy forever.”
“Ben’s biggest fear before he passed away was that he would be forgotten,” Green told Fox News Digital.
“I hope that my work and the development of this new drug makes him proud and carries on his legacy forever, ensuring that he is not completely forgotten.”
More research is needed, says the oncologist
Dr. Susannah Cooper, a board-certified oncologist and hematologist Arizona Oncology, reviewed the study but was not involved in the research. He told Fox News Digital that the results of these preliminary tests are promising.
Little progress has been made in the treatment of bone cancer over the past four decades, doctors said — telling a Fox News Digital, “New treatment approaches are essential to achieving better patient outcomes.” (iStock)
“There are some cancers that have limited response to conventional treatments, and a subset of primary bone cancers fall into this category,” Dr. Cooper said in an email. Cooper said in an email.
“As a result, little progress has been made in their conservation over the last 40 years. New methods of treatment This is essential to ensure the best outcomes for patients.”
Colorectal cancer showing up in younger people and in more advanced stages: study
Although Cooper is encouraged by CADD522 shrinking tumors and improving survival in cell cultures and animal models, he points out that there are still There is a lot of research to be done Before this, this drug will be used in the treatment of bone cancer.
The new drug has resulted in a 50% increase in survival rates for all major types of bone cancer.
“However, it highlights how understanding tumors at the molecular level and creating drugs that specifically target genes responsible for cancer initiation and development may lead to better responses with fewer side effects,” Cooper said. can,” Cooper said.
“This method of drug development has changed the shape of cancer care in recent years and is currently used in almost all cancer types.”
Up to this point, bone cancer treatments have primarily consisted of high-dose chemotherapy and surgery. (iStock)
Up to this point, treatments for bone cancer have primarily involved high-dose chemotherapy — which can have significant side effects — and surgery, which sometimes involves amputation of the affected limb.
Green hopes that if his team secures the necessary funding, they can conduct a clinical trial for patients within two to three years.
Click here to sign up for our health newsletter
Osteosarcoma, the most common type of bone cancer, primarily affects the Children and young adultsThe Mayo Clinic states on its website.
Click here to get the Fox News app
The American Cancer Society estimates that approximately 3,970 new cases of bone cancer will be diagnosed in 2023.
About 2,140 people are expected to die from the disease this year.
